These guys have grown to big for their britches. It would be considerate of them to provide a time and location of the "special meeting".
From the form 14: Dear Stockholder: Notice is hereby given that a Special Meeting of Stockholders (the “Special Meeting”) of Innovation Pharmaceuticals Inc., a Nevada corporation (the “Company”), will be held on [______], September [__], 2019 at [_____] a.m., local time, at [__________], for the following purposes:
From the 7/29/19 pr(based on todays form 14 filing, I'm beinning to think that following will put in same drawer as "nazdaq lising", P2b interim, 2017 partnering, 20 patient ph 2 k, 3rd q2017 P 2b trial completion) :
Bertolino continued: “The Alfasigma licensing agreement, importantly, enables us to access non-dilutive capital immediately and potentially into the future, via structured milestone-based payments and royalties. Equally important, we can now dedicate further internal resources to moving our clinical portfolio ahead—developing novel oral medications for hard-to-treat diseases like IBD, Oral Mucositis and Cancer. Successfully completing additional strategic alliances and licensing deals remains a primary objective, towards which we are making notable progress, with multiple active advanced-stage negotiations ongoing. We are excited about the Company’s prospects heading into the second-half of 2019, and anticipate providing future updates as events unfold.”
